Navigation Links
NIAID funds clinical trials that address the problem of antimicrobial resistance
Date:9/2/2009

Scientists are addressing the threat of antimicrobial drug resistance by launching two new clinical trials aimed at prolonging the effectiveness of currently available antibacterial drugs. The concept underlying both studies: Less is more.

The six-year contracts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, are part of an initiative intended to help answer key questions about proper antimicrobial doses, treatment duration and whether antimicrobial treatment is necessary in all cases. NIAID has made an initial award of $1.5 million to the Children's Hospital of Philadelphia with further funding of up to a total of $13.8 million available over the six-year course of the contract if clinical trial milestones are met. Duke University, Durham, N.C., has received an initial award of $1.4 million. If milestones are met, the total award from NIAID to the Duke team could total up to $11 million over six years.

Many infectious diseases are increasingly difficult to treat because bacteria and other microbes have developed resistance to commonly used antimicrobial drugs. Microbial drug resistance is driven by a variety of forces, including expanded use of antimicrobial drugs in human and animal healthcare. According to one estimate, between 5 and 10 percent of all hospitalized patients in the United States develop a drug-resistant infection of some kind, leading to an added $5 billion in annual healthcare costs.

"The clinical trials supported by this important initiative will provide vital information on the optimal use of antimicrobial drugs in a variety of clinical settings," says NIAID Director Anthony S. Fauci, M.D. "This information is critical to improving patient care and slowing the development of drug resistance."

Reducing the risk of antimicrobial resistance is a priority for NIAID, as exemplified by these new trials and two similar studies now under way. NIAID has also intends to fund additional innovative proposals aimed at slowing the development of antimicrobial resistance through targeted clinical trials. "Historically, development of new antimicrobials has moved at a much slower pace than the evolution of resistance to those treatments, so we need to look at preserving the usefulness of the drugs we have," says Dennis M. Dixon, Ph.D., chief of the Bacteriology and Mycology Branch within NIAID's Division of Microbiology and Infectious Diseases. "One way to reduce the risk of resistance, and therefore to preserve antimicrobials, is to reduce unnecessary use of these drugs."

In the new round of research, investigators at Children's Hospital of Philadelphia will study children with urinary tract infections to determine if treatment with antimicrobials can be shortened from the standard length of up to two weeks and still be effective. The study will enroll as many as 1,000 children.

The Duke study also will test the effectiveness of shorter duration of antimicrobial treatment. This project will focus on hospitalized patients who acquire staphylococcal infections in the bloodstream after use of an intravenous catheter. This study could lead to reduced drug exposure in patients with such infections, which in turn lowers the chance that bacteria will develop resistance to the drugs. The conditions studied in these trialsinfections in the urinary tract or the bloodstreamare ones where development of antimicrobial resistance is of particular concern.

Christine Chiou, M.D., is the NIAID program officer overseeing the projects at Children's Hospital of Philadelphia and at Duke. The projects are part of a second round of funding to support research on optimal ways to treat bacterial infections while minimizing development of antimicrobial resistance. The first awards were made in 2007 to the University of California, Los Angeles, and the University of California, San Francisco (http://www3.niaid.nih.gov/news/newsreleases/2007/ca-mrsa_contracts.htm).


'/>"/>

Contact: NIAID Office of Communications
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. NIAID Awards New Grant to Expand Studies of Peregrines Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers
2. NIAID to fund new human immune profiling research centers
3. NIAID media availability: Still searching for predictors of asthma attacks
4. NIAID set to launch clinical trials to test 2009 H1N1 influenza vaccine candidates
5. NIAID media availability: New strategy proposed for designing antibody-based HIV vaccine
6. J. Craig Venter Institute Awarded $43 Million, Five Year Contract From NIAID to Continue to Develop and Provide Sequencing, Genotyping, and Bioinformatics Expertise and Services in Infectious Diseases
7. NIAID and Chinese officials sign agreement to foster TB research in Chinas Henan province
8. NIAID honors AIDS activist Martin Delaney
9. NIAID media availability: Seizures following parasitic infection associated with brain swelling
10. NIAID awards contracts to search for protein markers of disease
11. NIAID creates HIV vaccine discovery branch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Charleston, SC (PRWEB) , ... February 22, 2017 , ... ... one of several sponsors of the Medical University of South Carolina (MUSC) Center on ... in Mount Pleasant, SC. “MUSC’s Center on Aging is a tremendous resource in our ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... patient advocates stress that the patient context (age, illness and life choices) should ... to mitigate their occurrence. In addition, all too often, studies regarding ...
(Date:2/22/2017)... ... February 22, 2017 , ... Apptricity® Corporation, a ... and spend management, today announced that Keppel Corporation has selected Apptricity Travel and ... , “We are excited to announce the partnership between Keppel and Apptricity ...
(Date:2/21/2017)... ... ... Author Michèle Wolff has a passion for using food as medicine ... about it for optimal health. Wanting to share her knowledge to the world, she ... Solutions ” (published by Balboa Press AU). , This book inspires readers to ...
(Date:2/21/2017)... ... 21, 2017 , ... Tripp Lite, a world-leading manufacturer of ... that meet the most current standards. , The adoption by the Centers for ... Protection Association (NFPA) 101 – Life Safety Code (LSC) and NFPA 99 – ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... DUBLIN , Feb. 22, 2017  Allergan ... is proud to be a Gold sponsor of ... National Educating America Tour." This tour commemorates AFA,s15 ... availability of services and programs. The tour will ... free memory screenings and displays of the AFA ...
(Date:2/22/2017)... According to a new market research report "Process ... and Services (Analyzers, Probes & Sensors), End - User (Pharmaceutical Manufacturers, CRO ... market is poised to reach USD 3.30 Billion by 2021 from USD ... 2021. Continue Reading ... ...
(Date:2/22/2017)... 22, 2017 The intersection ... and more prevalent today resulting in identifying and ... as well as other botanicals for discovering the ... marijuana therapies and their applications. Cannabis companies are ... designed to bring the new therapies to the ...
Breaking Medicine Technology: